Transarterial radioembolization (TARE) is a locoregional radiopharmaceutical therapy based on the delivery of radioactive 90Y microspheres to liver tumors. The importance of personalized dosimetry to make TARE safer and more effective has been demonstrated in recent clinical studies, stressing the need for quantification of the dose-response relationship to ultimately optimize the administered activity before treatment and image it after treatment. 90Y dosimetric studies are challenging because of the lack of accurate and precise methods but are best realized with PET combined with Monte Carlo simulations and other image modalities to calculate a segmental dose distribution. The aim of this study was to assess the suitability of imaging 90Y PET patients with the total-body PET/CT uEXPLORER and to investigate possible improvements in TARE 90Y PET-based dosimetry. The uEXPLORER is the first commercially available ultra-high-resolution (171 cps/kBq) total-body digital PET/CT device with a 194-cm axial PET field of view that enables the whole body to be scanned at a single bed position. Methods: Two PET/CT scanners were evaluated in this study: the Biograph mCT and the total-body uEXPLORER. Images of a National Electrical Manufacturers Association (NEMA) image-quality phantom and 2 patients were reconstructed using our standard clinical oncology protocol. A late portal phase contrast-enhanced CT scan was used to contour the liver segments and create corresponding volumes of interest. To calculate the absorbed dose, Monte Carlo simulations were performed using Geant4 Application for Tomographic Emission (GATE). The absorbed dose and dose-volume histograms were calculated for all 6 spheres (diameters ranging from 10 to 37 mm) of the NEMA phantom, the liver segments, and the entire liver. Differences between the phantom doses and an analytic ground truth were quantified through the root mean squared error. Results: The uEXPLORER showed a higher signal-to-noise ratio at 10- and 13-mm diameters, consistent with its high spatial resolution and system sensitivity. The total liver-absorbed dose showed excellent agreement between the uEXPLORER and the mCT for both patients, with differences lower than 0.2%. Larger differences of up to 60% were observed when comparing the liver segment doses. All dose-volume histograms were in good agreement, with narrower tails for the uEXPLORER in all segments, indicating lower image noise. Conclusion: This patient study is compelling for the use of total-body 90Y PET for liver dosimetry. The uEXPLORER scanner showed a better signal-to-noise ratio than mCT, especially in lower-count regions of interest, which is expected to improve dose quantification and tumor dosimetry.
Transarterial radioembolization (TARE) is a locoregional radiopharmaceutical therapy based on the delivery of radioactive 90Y microspheres to liver tumors. The importance of personalized dosimetry to make TARE safer and more effective has been demonstrated in recent clinical studies, stressing the need for quantification of the dose-response relationship to ultimately optimize the administered activity before treatment and image it after treatment. 90Y dosimetric studies are challenging because of the lack of accurate and precise methods but are best realized with PET combined with Monte Carlo simulations and other image modalities to calculate a segmental dose distribution. The aim of this study was to assess the suitability of imaging 90Y PET patients with the total-body PET/CT uEXPLORER and to investigate possible improvements in TARE 90Y PET-based dosimetry. The uEXPLORER is the first commercially available ultra-high-resolution (171 cps/kBq) total-body digital PET/CT device with a 194-cm axial PET field of view that enables the whole body to be scanned at a single bed position. Methods: Two PET/CT scanners were evaluated in this study: the Biograph mCT and the total-body uEXPLORER. Images of a National Electrical Manufacturers Association (NEMA) image-quality phantom and 2 patients were reconstructed using our standard clinical oncology protocol. A late portal phase contrast-enhanced CT scan was used to contour the liver segments and create corresponding volumes of interest. To calculate the absorbed dose, Monte Carlo simulations were performed using Geant4 Application for Tomographic Emission (GATE). The absorbed dose and dose-volume histograms were calculated for all 6 spheres (diameters ranging from 10 to 37 mm) of the NEMA phantom, the liver segments, and the entire liver. Differences between the phantom doses and an analytic ground truth were quantified through the root mean squared error. Results: The uEXPLORER showed a higher signal-to-noise ratio at 10- and 13-mm diameters, consistent with its high spatial resolution and system sensitivity. The total liver-absorbed dose showed excellent agreement between the uEXPLORER and the mCT for both patients, with differences lower than 0.2%. Larger differences of up to 60% were observed when comparing the liver segment doses. All dose-volume histograms were in good agreement, with narrower tails for the uEXPLORER in all segments, indicating lower image noise. Conclusion: This patient study is compelling for the use of total-body 90Y PET for liver dosimetry. The uEXPLORER scanner showed a better signal-to-noise ratio than mCT, especially in lower-count regions of interest, which is expected to improve dose quantification and tumor dosimetry.
Authors: Etienne Garin; Laurence Lenoir; Yan Rolland; Julien Edeline; Habiba Mesbah; Sophie Laffont; Philippe Porée; Bruno Clément; Jean-Luc Raoul; E Boucher Journal: J Nucl Med Date: 2012-02 Impact factor: 10.057
Authors: Pietro Majno; Gilles Mentha; Christian Toso; Philippe Morel; Heinz O Peitgen; Jean H D Fasel Journal: J Hepatol Date: 2013-11-06 Impact factor: 25.083
Authors: Siddharth A Padia; Guy E Johnson; Kathryn J Horton; Christopher R Ingraham; Matthew J Kogut; Sharon Kwan; Sandeep Vaidya; Wayne L Monsky; James O Park; Renuka Bhattacharya; Daniel S Hippe; William P Harris Journal: J Vasc Interv Radiol Date: 2017-03-30 Impact factor: 3.464
Authors: Pierce K H Chow; Mihir Gandhi; Say-Beng Tan; Maung Win Khin; Ariunaa Khasbazar; Janus Ong; Su Pin Choo; Peng Chung Cheow; Chanisa Chotipanich; Kieron Lim; Laurentius A Lesmana; Tjakra W Manuaba; Boon Koon Yoong; Aloysius Raj; Chiong Soon Law; Ian H Y Cua; Rolley R Lobo; Catherine S C Teh; Yun Hwan Kim; Yun Won Jong; Ho-Seong Han; Si-Hyun Bae; Hyun-Ki Yoon; Rheun-Chuan Lee; Chien-Fu Hung; Cheng-Yuan Peng; Po-Chin Liang; Adam Bartlett; Kenneth Y Y Kok; Choon-Hua Thng; Albert Su-Chong Low; Anthony S W Goh; Kiang Hiong Tay; Richard H G Lo; Brian K P Goh; David C E Ng; Ganesh Lekurwale; Wei Ming Liew; Val Gebski; Kenneth S W Mak; Khee Chee Soo Journal: J Clin Oncol Date: 2018-03-02 Impact factor: 44.544